Latest Annual Report
Filed: 2026-03-17
Key Insights
- The company's revenue and earnings growth appear to be slowing, which could be a concern for investors.
- The company has undertaken cost reduction initiatives, including consolidating discovery research activities, which may impact future R&D and operational capabilities.
- The company's collaboration agreements with Novartis, Ionis, and others continue to be an important part of its business strategy, but the expiration or amendment of these agreements could have a significant impact on the company's financial performance.